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Abstract
© 2017 Wolters Kluwer Health,  Inc.  Preoperative chemotherapy and radiation for  localized
esophageal  cancer  produces cure rates  near  30% when combined with  surgical  resection.
Vandetanib, a small molecule receptor tyrosine kinase inhibitor of VEGFR-2, VEGFR-3, RET, and
EGFR,  demonstrated  synergy  with  radiation  and  chemotherapy  in  preclinical  models.  We
conducted a phase I study to assess the safety and tolerability of vandetanib when combined
with preoperative chemoradiation in patients with localized esophageal carcinoma who were
surgical  candidates.  Methods:  Patients  with  stage  II-III  esophageal  and  gastroesophageal
junction carcinoma without  prior  therapy were enrolled in  a  3+3 phase I  design.  Patients
received  once-daily  vandetanib  (planned  dosing  levels  of  100,  200,  and  300  mg)  with
concomitant  daily  radiotherapy  (1.8  Gy/d,  45  Gy  total)  and  chemotherapy,  consisting  of
infusional 5-FU (225 mg/m 2/d over 96 h, weekly), paclitaxel (50 mg/m 2, days 1, 8, 15, 22, 29)
and carboplatin (AUC of 5, days 1, 29). Results: A total 9 patients were enrolled with 8 having
either distal esophageal or gastroesophageal junction carcinomas. All patients completed the
planned  preoperative  chemoradiation  and  underwent  esophagectomy.  Nausea  (44%)  and
anorexia  (44%)  were  the  most  common  acute  toxicities  of  any  grade.  One  grade  4
nonhematologic toxicity was observed (gastrobronchial fistula). One additional patient suffered
a  late  complication,  a  fatal  aortoenteric  hemorrhage,  not  definitively  related  to  the
investigational regimen. Five (56%) patients achieved a pathologic complete response. Three
(33%) additional patients had only microscopic residual disease. Five (56%) patients remain
alive and disease free with a median follow-up of 3.7 years and median overall survival of 3.2
years. The maximum tolerated dose was vandetanib 100 mg/d. Conclusions: Vandetanib at 100
mg  daily  is  tolerable  in  combination  with  preoperative  chemotherapy  (5-FU,  paclitaxel,
carboplatin) and radiation therapy with encouraging efficacy worthy of future study.
http://dx.doi.org/10.1097/COC.0000000000000171
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